Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

European Heart Journal

Volumn 35, Issue 28, 2014, Pages 1897-1906

  Dorian, Paul ^a   Kongnakorn, Thitima ^b   Phatak, Hemant ^c   Rublee, Dale A ^d   Kuznik, Andreas ^d   Lanitis, Tereza ^e   Liu, Larry Z ^d,f   Iloeje, Uchenna ^c   Hernandez, Luis ^b   Lip, Gregory Y H ^g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b EVIDERA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e EVIDERA   (United Kingdom)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Apixaban; Aspirin; Atrial fibrillation; Cost effectiveness; Stroke prevention; Vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNITED KINGDOM; ANTAGONISTS AND INHIBITORS; BLEEDING; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DRUG COSTS; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; VITAMIN K; WARFARIN;

EID: 84904630569     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu006     Document Type: Article

References (36)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-1564
2. Di Carlo A. Human and economic burden of stroke. Age Ageing 2009;38:4-5
3. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Guidelines ESCCf P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document R, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbuchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719-2747
4. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867
5. Gallagher AM, Setakis E, Plumb JM, Clemens A, Van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968-977
6. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010;123:638-645 e4
7. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. on behalf of the AI. Efficacy and safety of apixaban compared with warfarin at different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation 2013;127:2166-76
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Committees A, Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992
9. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O-Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S. Committee AS, Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364: 806-817
10. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. Force I-SMGRPT. State-Transition modeling: A report of the ISPOR- SMDMModelingGood Research Practices Task Force-3. Value Health 2012;15:812-820
11. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J 2012;76:2289-2304
12. Ariesen M, Claus S, Rinkel G, Algra A. Risk factors for intracerebral hemorrhage in the general population: A systematic review. Stroke 2003;34:2060-2065
13. Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497
14. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC. Committees A, Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012;11:503-511
15. Claassen D, Kazemi N, Zubkov A, Wijdicks E, Rabinstein A. Restarting anticoagulation therapy after warfarin-Associated intracerebral hemorrhage. Arch Neurol 2008; 65:1313-1318
16. Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Costeffectiveness of warfarin: Trial versus 'real-world- stroke prevention in atrial fibrillation. Am Heart J 2009;157:1064-1073
17. Human Mortality Database. 2009 UK life tables. http://www. mortality. org/cgibin/hmd/country. php?cntr=GBR&level=2 (May 2011
18. National Institute for Health and Clinical Excellence (January 2009) The Guidelines Manual. London: National Institute for Health and Clinical Excellence. Available from: Www. nice. org. uk
19. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11
20. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs. warfarin for secondary stroke prevention in atrial fibrillation. Neurology 2012;79: 1428-1434
21. Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One 2012;7:e47473
22. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81
23. National Institute of Clinical Excellence (NICE). Atrial fibrillation: Dabigatran etexilate; final appraisal determination; 01 November 2011
24. Huybrechts K, Caro J, Xenakis J. The prognostic value of the modified rankin scale score for long-Term survival after first-ever stroke. Cerebrovasc Dis 2008;26: 381-387
25. Scarborough P BP. Coronary Heart Disease Statistics 2010 edition. British Health Foundation Health Promotion research group, Department of Public Health, University of Oxford
26. Sullivan P, Slejko J, Sculpher M, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011;31:800-804
27. Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: Report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007;28:2346-2353
28. Henriksson K, Farahmand B, Johansson S, Asberg S, Terent A, Edvardsson N. Survival after stroke: The impact of CHADS2 score and AF. Intl J Cardiol 2010;141:18-23
29. Brønnum-Hansen H, Davidsen M, Thorvaldsen P. Long-Term survival and causes of death after stroke. Stroke 2001;32:2131-2136
30. Bronnum-Hansen H, Jorgensen T, Davidsen M, Madsen M, Osler M, Gerdes LU, Schroll M. Survival and cause of death after myocardial infarction: The Danish MONICA study. J Clin Epidemiol 2001;54:1244-1250
31. Stewart S, Hart CL, Hole DJ, McMurray JJ. Apopulation-based study of the long-Term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359-364
32. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-1836
33. Monthly Index of Medical Specialties (MIMS), October 2011. http://www. mims. co. uk
34. Department of Health, National Schedule of Reference Costs Year: '2009-10-NHS Trusts and PCTs combined. http://www. dh. gov. uk/en/ Publicationsand statistics/Publications/PublicationsPolicyAndGuidance/DH-131140 (11 February 2013
35. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003;21(Suppl. 1):43-50
36. Beswick AD, Rees K, Griebsch I, Taylor FC, Burke M, West RR, Victory J, Brown J, Taylor RS, Ebrahim S. Provision, uptake and cost of cardiac rehabilitation programmes: Improving services to under-represented groups. Health Technol Assess 2004;8:1-152.